Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Certara, Inc. (NASDAQ:CERT) have been given an average recommendation of “Hold” by the nine research firms that are covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $17.79.

A number of equities analysts have recently issued reports on the stock. KeyCorp lowered their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. UBS Group decreased their target price on shares of Certara from $20.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Barclays reduced their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday, June 28th. Finally, Robert W. Baird lowered their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Certara Price Performance

Shares of NASDAQ:CERT opened at $10.90 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. Certara has a 12 month low of $10.35 and a 12 month high of $19.87. The firm has a market capitalization of $1.75 billion, a P/E ratio of -27.95, a P/E/G ratio of 5.23 and a beta of 1.49. The company’s fifty day moving average price is $13.26 and its 200 day moving average price is $15.40.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.10 earnings per share. As a group, sell-side analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Activity at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.39% of the company’s stock.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently modified their holdings of the company. Pineridge Advisors LLC acquired a new position in Certara during the fourth quarter worth $28,000. Blue Trust Inc. purchased a new stake in shares of Certara in the 2nd quarter worth about $26,000. Innealta Capital LLC acquired a new stake in Certara in the 2nd quarter valued at about $36,000. YHB Investment Advisors Inc. purchased a new position in Certara during the 1st quarter valued at about $47,000. Finally, Intech Investment Management LLC acquired a new position in Certara during the second quarter worth about $152,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.